Posted by Michael Wonder on 26 Jun 2021
Mirati Therapeutics' adagrasib receives breakthrough therapy designation from U.S. FDA for patients with advanced non-small cell lung cancer harbouring the KRASG12C mutation
24 June 2021 - Mirati Therapeutics announced today that the U.S. FDA has granted breakthrough therapy designation to adagrasib for the potential treatment of patients with non-small cell lung cancer who harbour the KRASG12C mutation following prior systemic therapy.
The designation for adagrasib is supported by preliminary results from the registrational Phase 1/2 KRYSTAL-01 trial in patients with advanced non-small cell lung cancer, whose cancer had progressed following prior treatment with immunotherapy and/or chemotherapy.
